Quinapril is an angiotensin converting enzyme (ACE) inhibitor. It works by blocking a substance in the body that causes blood vessels to tighten. As a result, quinapril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood to tissues. Quinapril is an ethyl ester prodrug that is enzymatically hydrolyzed to the active diacid metabolite quinaprilat; inhibition of ACE reduces formation of angiotensin II and decreases aldosterone release, lowering systemic vascular resistance and preload. Clinically this effect reduces hypertension and can improve cardiac workload in heart failure. Quinapril is absorbed orally, undergoes first pass conversion to quinaprilat, and is primarily eliminated by renal excretion; dosing and monitoring are adjusted for renal function because exposure to the active metabolite increases with reduced clearance.
Parent: Enalapril / Trandolapril/ Ramipril/ Quinapril / Spirapril/ Moexipril/ Enalaprilat
Parent: Quinapril
Parent: Quinapril
Parent: Quinapril
Parent: Quinapril / Quinapril Hydrochloride
Typical impurity and related compound profiles for quinapril API include hydrolysis products and process-related impurities such as quinaprilat (active metabolite), the diketopiperazine (DKP) cyclization product, N-dealkylated derivatives, epimerization isomers and oxidative byproducts; these are monitored by validated HPLC or LC-MS methods. Manufacturing specifications commonly control individual known impurities in the range of about 0.10 to 0.50 percent w/w depending on qualification status, with unspecified impurities reported at lower thresholds such as 0.10 percent w/w and total impurities typically limited to approximately 1.0 to 1.5 percent w/w; specific limits vary by manufacturer and regulatory filing. Stability testing focuses on moisture-driven hydrolysis to DKP and epimer formation under acidic or basic conditions, and acceptable limits are established based on degradation pathways, toxicological qualification and regulatory guidance.
Quinapril is used to treat high blood pressure and to manage certain forms of heart failure; by lowering blood pressure it also helps reduce the risk of stroke and myocardial infarction in appropriate patients as determined by a prescriber.
No. Quinapril is not a beta blocker. It is an ACE inhibitor and works by blocking angiotensin converting enzyme rather than blocking beta adrenergic receptors.
Avoid potassium supplements and potassium-sparing diuretics unless supervised by a prescriber because quinapril can increase serum potassium. Avoid sudden use of nonsteroidal anti-inflammatory drugs for long periods without medical review, and avoid significant alcohol use that can worsen blood pressure control. Also inform the prescriber before major surgery or contrast dye procedures, because temporary discontinuation may be recommended in some cases.
Quinapril has not been uniformly discontinued worldwide, but availability can change for commercial reasons such as manufacturing decisions, patent and market dynamics, or regulatory actions related to quality issues for specific batches. If a particular brand or formulation was discontinued consult the manufacturer or regulatory database for the stated reason and speak with a healthcare provider about alternative ACE inhibitors.
